$heff's $tation of $tocks & $olid DD

[bra1loga]

DSCO - Stifel has a $5 target for the stock, and the consensus target is also lofty at $4.83. The stock closed Tuesday at $1.75.

Discovery Laboratories Inc. (NASDAQ: DSCO) is a specialty biotechnology company focused on advancing new standards in respiratory critical care. Its technology platforms include a novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant. Discovery Labs' strategy is initially focused on neonatology and improving the management of respiratory distress syndrome in premature infants. Stifel feels the pipeline at the company centered around FDA-approved Surfaxin can expand beyond current infant use to other respiratory disorders. The estimate for the current market for the drug is in the $150 million to $200 million range.